• Wondering if Veeva Systems at around US$167.95 is offering fair value or a potential bargain? This article breaks down what the current price might really imply.
• The stock has recently moved 10.9% over the past week, while returns over 30 days, year to date, 1 year and 5 years are negative. This may leave you questioning whether the recent move reflects changing expectations or just short term noise.
• Recent commentary around Veeva Systems has focused on its role within healthcare and life sciences software, with investors weighing how its position in this niche fits into long term digital transformation trends. At the same time, the stock's performance figures have kept attention on whether expectations built into the price align with what the business is delivering.
• Veeva Systems currently scores a 3 out of 6 valuation score. The sections ahead will walk through what different valuation approaches say about that number and finish with a way to assess value that goes beyond the usual ratios.

Approach 1: Veeva Systems Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today, aiming to translate those projections into a single present value per share.

For Veeva Systems, the model uses current last twelve month free cash flow of about $1.39b and a 2 Stage Free Cash Flow to Equity approach. Analysts provide free cash flow projections for the next few years, then Simply Wall St extrapolates further out, with projected free cash flow reaching about $2.43b in the year to 2031. These yearly cash flows are discounted back to today and combined with a longer term value beyond the explicit forecast period.

On this basis, the DCF estimate points to an intrinsic value of about $271.60 per share, compared with a recent share price of around $167.95. That gap implies the stock is trading at roughly a 38.2% discount to the DCF value. In this model, the current price is described as being well below the estimated intrinsic value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Veeva Systems is undervalued by 38.2%. Track this in your watchlist or portfolio, or discover 59 more high quality undervalued stocks.

Approach 2: Veeva Systems Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about value because it links the share price directly to current earnings. It effectively tells you how many dollars investors are paying today for each dollar of earnings.

What counts as a "normal" P/E depends on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower expected growth or higher perceived risk tends to justify a lower one.

Veeva Systems is currently trading on a P/E of about 30.18x. That sits close to both the Healthcare Services industry average of roughly 29.42x and the peer average of about 30.88x. Simply Wall St also provides a proprietary “Fair Ratio” of 28.81x, which estimates the P/E that might be appropriate given Veeva Systems earnings growth profile, industry, profit margins, market cap and risk factors.

This Fair Ratio goes a step beyond simple peer or industry comparisons, because it adjusts for company specific characteristics rather than assuming one size fits all. Comparing the current 30.18x P/E to the 28.81x Fair Ratio suggests the shares are priced somewhat above that tailored estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Veeva Systems Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St that takes the form of Narratives. In this approach, you set out your view of Veeva Systems in a short story that links its role in life sciences software to your own assumptions for future revenue, earnings and margins. The platform then converts this into a financial forecast, a Fair Value and a simple comparison to the current price on the Community page. This page updates automatically when new news or earnings arrive. One investor might back a higher Fair Value near US$380 if they see AI agents, Development Cloud and data products supporting stronger growth and higher margins. Another might anchor closer to US$232.80 if they expect revenue growth and profitability to track the more cautious analyst case. Both can quickly see how those views stack up against today’s share price of about US$167.95.

Do you think there's more to the story for Veeva Systems? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.